Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.43 |
| ▸ | WNT3A | P56704 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 9/20 | 0.42 |
| ▸ | CA12 | O43570 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276241 | 0.81 | CYP2A6 (0.41) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL164774 | 0.73 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL17010916 | 0.73 | CYP2A6 (0.52) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL534539 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL2011544 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL760406 | 0.71 | CYP2A6 (0.55) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL153350 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL18725846 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL155613 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL226062 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115341-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| EP-1636192-B9 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| EP-1636192-B1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-8552031-B2 | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8093251-B2 | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| US-6384065-B1 | CONTROL THE FUNCTIONS OF PROTEINS SUCH AS ENZYMES AND RECEPTOR FORTREATING INFLAMMATORY DISEASES SUCH AS RHEUMATOID ARTHRITIS, | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-0662964-B1 | HETEROCYCLIC AMINES HAVING CALMODULIN ANTAGONIST PROPERTIES | BRITISH TECH GROUP (GB) | 1997-06-11 | — | — | EP | disclosed |
| US-5543422-A | HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS, FUNGICIDES | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1996-08-06 | — | — | US | disclosed |
| EP-0662964-A1 | HETEROCYCLIC AMINES HAVING COLMODULIN ANTAGONIST PROPERTIES. | BRITISH TECH GROUP (GB) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994007875-A1 | HETEROCYCLIC AMINES HAVING COLMODULIN ANTAGONIST PROPERTIES | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1994-04-14 | — | — | WO | disclosed |
| EP-0342891-B1 | Fluorescent intracellular calcium indicators | SMITHKLINE BEECHAM CORP (US) | 1994-03-09 | — | — | EP | disclosed |
| EP-0342891-A1 | Fluorescent intracellular calcium indicators | SMITHKLINE BEECHAM CORPORATION (US) | 1989-11-23 | — | — | EP | disclosed |
| US-4849362-A | Fluorescent intracellular calcium indicators | SMITHKLINE BECKMAN CORPORATION (US) | 1989-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | CYP2A6 630/4885DYRK1A 2916/4885PTPRC 1058/4885 |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | CYP2A6 630/4885DYRK1A 2916/4885PTPRC 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.